Ditchcarbon
  • Contact
  1. Organizations
  2. OptiNose, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 3 months ago

OptiNose, Inc. Sustainability Profile

Company website

OptiNose, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on innovative solutions for patients suffering from chronic sinusitis and other nasal conditions. Founded in 2010, OptiNose has made significant strides in the industry, particularly with its unique delivery systems that enhance the efficacy of medications. The company’s flagship products, including the Xhance nasal spray, leverage advanced technology to improve drug absorption and patient compliance. With a commitment to addressing unmet medical needs, OptiNose has established a strong market position, recognised for its contributions to the field of nasal therapeutics. As it continues to expand its operational reach, OptiNose remains dedicated to transforming the treatment landscape for patients worldwide.

DitchCarbon Score

How does OptiNose, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

OptiNose, Inc.'s score of 25 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.

37%

Let us know if this data was useful to you

OptiNose, Inc.'s reported carbon emissions

OptiNose, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. As a current subsidiary, OptiNose, Inc. may inherit climate-related data and initiatives from its parent organisation, but no specific details have been provided regarding such cascaded information. The absence of emissions data and reduction initiatives places OptiNose, Inc. in a context where it may need to enhance its climate commitments to align with industry standards and expectations. Overall, while OptiNose, Inc. has not disclosed any emissions or reduction targets, the company is positioned to develop a more robust climate strategy in the future.

How Carbon Intensive is OptiNose, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. OptiNose, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is OptiNose, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for OptiNose, Inc. is in US, which has a low grid carbon intensity relative to other regions.

OptiNose, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

OptiNose, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare OptiNose, Inc.'s Emissions with Industry Peers

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Genentech USA, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Merck Sharp & Dohme LLC

US
•
Pharmaceutical Preparation Manufacturing
Updated 17 days ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated about 11 hours ago

Boehringer Ingelheim International GmbH

DE
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Horizon Therapeutics Public Limited Company

IE
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251119.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy